iBio (IBIO) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Strategic focus and portfolio development

• Emphasis on developing second-generation obesity drugs targeting unmet needs beyond GLP-1s, such as muscle preservation and sustainable weight loss.

• Portfolio includes myostatin (IBIO-600), bispecific myostatin/activin A antibody, and a selective amylin receptor antibody.

• Activin E antibody program aims to enable fat-specific weight loss and long-term weight maintenance.

• Amylin program designed for high selectivity, avoiding calcitonin receptor binding to improve safety.

• Pipeline addresses both obesity and cardiovascular indications, including HFpEF.

Clinical progress and timelines

• IBIO-610 (activin E) completed non-human primate studies; initial data readouts expected in 30–60 days, with further data at ADA, ObesityWeek, and EASD meetings.

• IND-equivalent filing for IBIO-610 planned in Australia in H2 2026, with first patient dosing in H1 2027.

• Bispecific myostatin/activin A program is 6 months behind IBIO-610, aiming for IND-equivalent filing in H1 or early H2 2027.

• IBIO-600 (myostatin) on track for first patient dose in Q3, with interim data expected late this year or early next year.

• Amylin program progressing toward a developmental candidate and IND-equivalent filing in H2 2025.

Scientific insights and differentiation

• Activin E antibody approach may achieve higher pathway inhibition than siRNA competitors, potentially enabling twice-yearly dosing.

• Preclinical data show fat-specific weight loss, synergy with GLP-1s, and potential for long-term weight maintenance.

• Amylin antibody is highly selective for receptors 1 and 3, avoiding calcitonin receptor to reduce adverse effects.

• Bispecific antibody for HFpEF targets myostatin, GDF11, and activin A, aiming for efficacy without bleeding risk seen in ligand traps.

• Competitive landscape is narrowing, with few differentiated programs remaining in the space.